2019 POSTER PRESENTATIONS
Main Conference Poster Sessions A & B - San Diego Convention Center
Symposia Posters - Hard Rock Hotel
Poster Presenters noted with * are Student Fellows.
POSTER SESSION A
Presenting Tuesday – Wednesday (morning)
Arabian Gulf University
A1. Computer-Aided Approach to Design Novel Leishmania Major Protein Disulfide Isomerase (LmPDI) Inhibitors; Presented by Noureddine B.
AssayQuant Technologies, Inc.
A2. CSox-Based Sensors for Homogeneous and Quantitative Monitoring of Protein Kinase and Phosphatase Activity Using Kinetic or Endpoint/Eu3+/Red Formats; Presented by Erik S.
Aurelia Bioscience
A3. Prosecution of the CDK Family Using NanoBRET Intracellular Engagement to Examine Clinically Relevant Inhibitors for Target Occupancy and Residency Time Measurements in Living Cells; Presented by Gary A.
Baylor College of Medicine
A4. Drugging the 'Undruggable' Steroid Receptor Coactivators; Presented by Jin W.
Biodesy, Inc.
A5. Discrimination of Kinase Conformational States upon Inhibitor Binding by Second-Harmonic Generation; Presented by Tracy Y.
BioSolveIT GmbH
A6. Exploring the Chemical Space; Presented by Franca K.
Boston University
A7. Structure-Activity Relationship Study of a Cyclic Nrf2 Peptide to Develop Potent Inhibitors of the KEAP1/Nrf2 Protein-Protein Interaction; Presented by Paula O.*
BPS Bioscience
A8. Improving Immunotherapy Through Immune Checkpoint Assays, CAR-T Target Display, and Effector Function Optimization; Presented by Stephen E.
Cfm Oskar Tropitzsch GmbH
A9. Payload with Novel Mode of Action; Presented by Michael S.
ChemDiv, Inc.
A10. Library of Covalent Fragments: Design and Synthesis; Presented by Volodymyr K.
Chemspace, Inc.
A11. Advantages of Fluorinated Fragment Library in the Discovery of Novel Specific Binders and Hit to Lead Optimization; Presented by Yurii M.
Chinese Academy of Medical Sciences & Peking Union Medical College
A12. S-31, a Novel STAT3 Inhibitor for Treatment of Human Cancers; Presented by Yuchen W.
Concept Life Sciences
A13. Development of WEE1 Inhibitors with Selectivity Against PLK1; Presented by Matilda B.
Cresset
A14. Flexible and Integrated Collaboration Tools to Aid, Coordinate and Inspire Small Molecule Discovery - Application to Kinase Inhibitors; Presented by Sylvie S.
CrystalsFirst GmbH
A15. How to Optimize the Fragment Hit Rate: Take Crystals First; Presented by Serghei G.
Domainex Ltd.
A16. MAP4K4 Mediates Human Cardiac Muscle Cell Death: Preserving Viability and Function in Human Pluripotent Stem Cell-Derived Cardiomyocytes; Presented by Katie C.
Domainex Ltd.
A17. Fragment-Based Drug Design Using Microscale Thermophoresis; Presented by Trevor P.
Edelris SAS
A18. Exploring New Chemical Spaces Towards Hit Generation; Presented by Jean-Yves O.
Ehime University
A19. Screening System for Chemical Compound-Dependent Binding Proteins Using Cell-Free Protein Array; Presented by Satoshi Y.*
Eurofins Pharma Discovery Services
A20. Combining the Power of Different Profiling Approaches to Better Understand the Activity of Kinase Inhibitor Drugs; Presented by Dan D.
Eurofins Pharma Discovery Services
A21. InCELL Pulse™: A Novel Cellular Target Engagement Assay Platform for Drug Discovery; Presented by Poonam K.
GE Healthcare
A22. Increased SPR-Sensitivity Enables Fragment Screening and Kinetic Characterization at Lower Surface Densities; Presented by Matthew B.
Haystack Sciences
A23. Reducing Noise and Assigning Hit Affinities in DNA-Encoded Libraries; Presented by Eddie W.
Key Organics Ltd.
A24. Building a Diverse and Experimentally-Curated Fragment Library; Presented by Andrew L.
Key Organics Ltd.
A25. NMR Curation for Compound Prioritization and Fragment Library Characterization; Presented by Andrew L.
Korea Institute of Science and Technology (KIST)
A26. SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia; Presented by Taebo S.
Life Chemicals, Inc.
A27. Novel Fragment Libraries from Life Chemicals; Presented by George B.
Life Chemicals, Inc.
A28. Screening Compound Libraries for HTS and Lead Discovery Projects; Presented by George B.
Lunenfeld-Tanenbaum Research Institute
A29. Anti-Cancer Drug Development to Modulate Hippo Pathway Function; Presented by Dohee L.
Monash University
A30. Efficient Development of Fragments via Biophysical Screening of Crude Parallel Libraries; Presented by Bradley D.
Philipps University Marburg
A31. Busted! Recognizing False Positives and False Negatives: Learnings from Comparative Analysis of Fragment Binding Using X-Ray Crystallography and NMR; Presented by Engi H.
Philipps University Marburg
A32. Exhaustive X-Ray Crystallographic Screening of a Hit-Enriched 96 Fragment Library Against Diverse Targets; Presented by Francesca M.*
Philipps University Marburg
A33. Frag4Lead - A Workflow for Efficient Fragment-Based Lead Discovery by Crystallography; Presented by Jan W.
Pohang University of Science and Technology (POSTECH)
A34. Development of Stapled Peptides Targeting NCOA1/STAT6 Protein-Protein Interaction; Presented by Yeongju L.*
Prestwick Chemical
A35. Prestwick Innovative Fragment-Based Tools to Support Drug Discovery; Presented by Christophe M.
Promega Corporation
A36. A Homogeneous Bioluminescent Immunoassay Approach to Interrogate Cellular Signaling Pathways Activation and Deactivation; Presented by Brian H.
Promega Corporation
A37. Bioluminescent Homogeneous Detection Assays for Screening for Modulators of Methylation and Demethylation; Presented by Kara M.
Reaction Biology Corporation
A38. Application of Novel BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells; Presented by Jianghong W.
SRI International
A39. Cancer-Specific Intracellular Delivery of Therapeutic Antibodies Against RAS; Presented by Susan L.
Touro University
A40. Small Molecules Targeting Protein-Protein or Protein-Lipid Interactions of HIV-1 gp41; Presented by Miriam G.
University of California, Riverside
A41. Dual Substrate and ATP Competitive JNK Inhibitors; Presented by Alex A.*
University of California, Riverside
A42. HTS by NMR for the Identification of Novel EphA3 Targeting Agents; Presented by Carlo B.
University of California, Riverside
A43. Design of Potent Pan-IAP and Lys-Covalent XIAP Selective Inhibitors with Optimization of the Reactive Warhead; Presented by Luca G.
University of California, Riverside
A44. Understanding the Molecular Basis for the Anticancer Activity of the Pan-IAP Antagonist, AZD5582; Presented by Parima U.*
University of Toronto
A45. HDAC-6 Selective Inhibitor Shows Potential as an Oral Drug Treatment for Acute Myeloid Leukemia; Presented by Nabanita N.*
University of Toronto
A46. Dynamic Conformational Tethering to Provide Pharmacokinetic Stability to an Electrophilic Warhead Group; Presented by Erica Q.*
University of Toronto
A47. Pharmacologic Intervention of STAT5; Presented by Gary T.*
University of Washington
A48. How Does eIF3 Recognize mRNA Structure During Specialized Translation Initiation?; Presented by Matthew W.*
Voronoi Bio
A49. Discovery of Selective and Potent EGFR Kinase Inhibitors for Exon 20 Ins Mutation; Presented by Juhee K.
Wroclaw Medical University
A50. 3PO - Small Molecule PFKFB3 Inhibitor Induce Apoptosis and Cell Cycle Arrest in A375 Human Melanoma Cell Line with Endogenous BRAFV600E Mutation; Presented by Krzysztof K.*
Yeditepe University
A51. Target Identification Using Theoretical Active Site Models; Presented by Belkis A.*
Yeditepe University
A52. Computational Evaluation of Potential Inhibitors for Protein Kinase CK2; Presented by Doga O.*
POSTER SESSION B
Presenting Wednesday (afternoon) - Thursday
Biodesy, Inc.
B1. Second-Harmonic Generation Based Detection of Ligand-Induced Conformational Changes in STING; Presented by Serra E.
Bio-Techne (Tocris)
B2. Generating a Chemical Toolbox to Support PROTAC Discovery; Presented by Hannah M.
Boryung Pharmaceuticals Co., Ltd.
B3. Identification of BR103354, Fibroblast Activation Protein (FAP) Inhibitor as a Novel Potential Therapeutic Agent for the Treatment of Multiple Diseases; Presented by Suk-Ho L.
Boston University
B4. Investigation of Macrocyclic Compounds as Inhibitors of the Protein-Protein Interaction Between B-Catenin and TCF4; Presented by Megan H.*
Boston University
B5. Machine Learning Analysis to Elucidate Design Guidelines for Synthetic Macrocycle Drugs; Presented by Lauren V.*
ChemDiv, Inc.
B6. Macrocyclic Peptidomimetics: Library Design and Synthesis; Presented by Volodymyr K.
Chemical Computing Group
B7. A Protocol for Validating Small Molecule Structure Assignment Using Calculated 13C NMR Chemical Shifts with Quantum Mechanics and MOE; Presented by Alain A.
Chemspace, Inc.
B8. Compound Library Targeted Protein-Protein Interactions; Presented by Oleksii G.
Domainex Ltd.
B9. MPL-7097, an ESM™ p38 MAPK Inhibitor; Presented by Katie C.
Domainex Ltd.
B10. Fragment Screening Against GPCRs by Mass Spectrometry Using a New Detergent-Free Technique for Receptor Preparation; Presented by Trevor P.
Enamine Ltd
B11. New Covalent Fragment Libraries by Parallel Synthesis; Presented by Tatiana M.
Enamine Ltd.
B12. Advanced Toolbox for PROTACs Synthesis; Presented by Tatiana M.
Fidelta Ltd.
B13. Macrolide Inspired Macrocycles as a Promising Templates for Unmet Medical Needs; Presented by Tanja P.
FIMECS, Inc.
B14. Targeted Degradation of Interleukin Receptor Associated Kinase-M (IRAK-M); Presented by Yoshihide T.
Genentech, Inc.
B15. Engineering the USP7 Catalytic Domain for Drug Discovery; Presented by Charlene B.
Gyros Protein Technologies
B16. Rapid Parallel Synthesis Optimization of Cyclic Peptides for Therapeutic Development; Presented by Cyf R.
Kwansei Gakuin University
B17. Allosteric Propagation in GPCR Structures; Presented by Adnan S.
leadXpro AG
B18. Structure-Based Lead Discovery and Optimization on GPCR Targets; Presented by Denis B.
Life Chemicals, Inc.
B19. PPI and Epigenetic Targeted Libraries from Life Chemicals; Presented by Vasily P.
Merck Research Laboratories
B20. Photoredox Ni-Catalyzed Peptide C(sp2)-O Cross-Coupling: From Intermolecular Reactions to Side Chain-to-Tail Macrocyclization; Presented by Hyelee L.
Mitsubishi Tanabe Pharma Corporation
B21. Design and Synthesis of Apratoxin A Mimetics; Presented by Yuichi O.
Pohang University of Science and Technology (POSTECH)
B22. Cell Permeability Comparison of α-ABpeptoids and Peptides; Presented by Min Jae K.*
Pohang University of Science and Technology (POSTECH)
B23. Synthesis and Circular Dichroism Investigations of a New Class of Heterogeneous Foldamers: β3-Peptide/α-ABpeptoid Hybrid Oligomers; Presented by Kang Ju L.*
Pohang University of Science and Technology (POSTECH)
B24. Cell Penetration Assessment of Bicyclic Peptoids; Presented by Hee Myeong W.*
Prestwick Chemical
B25. Original Peptidic Macrocycle Library: An Innovative Screening Tool for Targeting Non-Conventional Chemical Space; Presented by Christophe M.
Promega Corporation
B26. Monitoring Functional Mechanisms of Protein Degradation in Living Cells; Presented by Neal C.
Promega Corporation
B27. Energy Transfer in Live Cells as a Method to Assess E3 Ligase and Target Protein Occupancy for PROTACs; Presented by Kristin H.
Sanford Burnham Prebys Medical Discovery Institute
B28. Testing Funnel for Identification and Validation of Positive Allosteric Modulators Targeting Secretin Receptors to Treat Heart Failure; Presented by Daniela D.*
SRI International
B29. Synthetic Macromolecules as High Affinity PPIs Identified by uHTS Using Fiber Optic Array Scanning Technology (FAST); Presented by Michal A.
State University of New York, Upstate Medical University
B30. Mechanistic Validation of a Novel Relaxin-3 B-Chain Stapled Peptide as a Preclinical Lead for Targeting Relaxin-3/RXFP3 Networks; Presented by Subhi M.
SungKyunKwan University
B31. Site-Selective Chemical Conjugation of Antibodies Based on IgG Fc-Binding Peptide; Presented by Sang C.
Thermo Fisher Scientific
B32. New Tools for the Expression, Purification and Characterization of Difficult to Express Membrane Proteins Using the Expi293 and ExpiCHO Expression Systems; Presented by Jonathan Z.
University of Bonn
B33. G Protein-Coupled Receptor 143: Looking for the "Ligand" in the Haystack; Presented by Beatriz B.*
University of California, San Diego
B34. Inhibition of Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 2 Perturbs 26S Proteasome-Adapted Multiple Myeloma; Presented by Sourav B.
University of California, Santa Cruz
B35. Membrane-Permeable Lariat Peptides; Presented by Colin K.*
University of California, Santa Cruz
B36. Improving upon Nature: A Medicinal Chemistry Optimization of Cordyheptapeptide A and B; Presented by Victoria K.*
University of California, Santa Cruz
B37. Identification of Cell-Permeable Cyclic Peptides in a DNA Encoded Library Through Reverse Phase Chromatography; Presented by Grant K.*
University of California, Santa Cruz
B38. Synthetic Cyclic Peptomers as Virulence Blockers that Suppress Pathogenicity of Antibiotic Resistant Bacteria; Presented by Tannia L.*
University of California, Santa Cruz
B39. The Permeability Landscape of Cyclic Hexa- and Heptapeptides; Presented by Chad T.*
University of Cambridge
B40. Multi-Site Inhibition of the Anaphase Promoting Complex/ Cyclosome (APC/C-Cdc20) Using Constrained Peptides; Presented by Rohan E.*
University of Cambridge
B41. Developing Constrained Peptides to Target an Oncogenic E3 Ubiquitin Ligase; Presented by Grasilda Z.*
Voronoi Bio
B42. Discovery and Preliminary Application of VRN1: Novel and Selective RIPK1 Kinase Inhibitor; Presented by Hua L.
Wroclaw Medical University
B43. Altered Biological Activity of Various Natural-Derived Substances in Normal and Cancer Cells; Presented by Daniel W.*
SYMPOSIA POSTER SESSION
Presenting Friday
Arabian Gulf University
S1. Machine Learning and Virtual Screening for the Identification of Novel PDIA1 Inhibitors; Presented by Noureddine B.
Biodesy, Inc.
S2. Second-Harmonic Generation (SHG) - A Novel On-Target and High-Throughput Technology for Small Molecule Screening by Detecting Structural Changes of Target Biomolecules; Presented by Serra E.
Chemical Computing Group
S3. Multi-Target Molecular Profiling Using MOE: CYP450 Isoform Selectivity Case Study; Presented by Petrina K.
Culgi BV
S4. Predicting the Membrane Permeability of Large Drugs; Presented by Hans F.
Eurofins Pharma Discovery Services
S5. Binding and Functional Analysis - Complementary Approaches in Safety Pharmacology; Presented by Haiyang W.
GE Healthcare
S6. Biacore™ SPR-Based Surrogate Potency Assays with Streamlined PLA and EC50 Analysis Facilitate Comparability Studies; Presented by Matthew B.
GE Healthcare
S7. Kinetic and Concentration Analysis in All Directions with Biacore™ 8K and Biacore 8K+; Presented by Cynthia S.
GE Healthcare
S8. Biacore™ 8K and Biacore 8K+ Offer Increased Flexibility and Capacity to Streamline the Drug-Discovery Workflow; Presented by Cynthia S.
GSI Technology, Inc.
S9. Hardware-Accelerated Drug Discovery; Presented by George W.
Mayo Clinic
S10. Induced-Fit Docking Method for Refining Drug-Receptor Optimization Driven by Maxwell's Demon Under QM Scoring Function; Presented by Thomas C.
Optibrium Ltd.
S11. Deep Learning Based on Sparse and Noisy Data to Improve Predictions of Compound Activities; Presented by Nicholas F.
Reaction Biology Corporation
S12. Developing SPR Assays to Directly Measure Binding to Epigenetic Targets; Presented by Rebecca E.
SRI International
S13. Rapid Machine Learning Route Design and Automated Synthesis of Drug-Like Molecules Demonstrated by the Continuous Multistep Synthesis of Three Nucleoside Antivirals in One Day on a Single Automated System; Presented by Nathan C.
Takeda California, Inc.
S14. The Utility and Performance of In Silico Off-Target Profiling in Early Drug Discovery; Presented by Takafumi T.
University of Lisbon
S15. Highly Specific Blood-Brain Barrier Single-Domain Antibodies Selected by In Vivo Phage Display Screenings; Presented by Frederico S.
University of Toronto
S16. Development of an Excimer-Based Fluorescence Assay for Discovery of Glycosyltransferase Inhibitors; Presented by Johan I.*
Wroclaw Medical University
S17. The Cytoprotective Role of Antioxidants in Mammalian Cells Exposed to Variable Temperature, Pressure Overload and Radiation in the Stratosphere; Presented by Dawid P.*